Contract Service Directory

FLAMMA





Company Headquarters

Via Bedeschi 22
Chignolo d'Isola (BG), 24040
Italia

Company Description

FLAMMA is a fully integrated CMO based near Milan, Italy that was established in 1950. FLAMMA is a company specialized in the cGMP manufacture of APIs, NCEs, RSMs & advanced intermediates for the pharma industry. Flamma has particular expertise in high value chiral materials specifically amino acid related materials. Flamma also manufactures specialty compounds & adv. intermediates for the nutraceutical & cosmetic. FLAMMA has 3 cGMP manufacturing facilities (2 Italy, 1 China). Flamma provides security when working in China with our 100% owned, self-managed facilities that deliver results without worry. Flamma offers full integration as well as cost-effective services to customers looking for a trusted partner within China. Flamma can be of assistance for early stage pre-clinical development of small molecules as well as for large-scale commercial manufacturing. With a total reactor capacity of 450 m3 & over 450 employees, see why Flamma should be YOUR NEXT CONTRACT MANUFACTURER.

Contract Service Directory

    Related Content

    • Breaking News | Facilities | Industry News
      PCI Pharma Services Invests in Tredegar, UK Site

      PCI Pharma Services Invests in Tredegar, UK Site

      Doubles capacity to expand development and manufacturing capabilities.
      12.11.19

    • Analytical Services | Breaking News | Industry News | Vials
      Stevanato Group Begins Construction on TEC

      Stevanato Group Begins Construction on TEC

      New facility supports company’s U.S.-centric biopharma drug development operations
      12.05.19

    • APIs | Breaking News | Industry News
      Indena Focuses on Pharma

      Indena Focuses on Pharma

      Sells cosmetics biz to focus on core markets.
      11.27.19


    • Industrial Equipment Auctions and Liquidations

      Industrial Equipment Auctions and Liquidations

      Industrial equipment auctions and liquidations are effective ways for companies to manage their facilities, fixed asset inventory, and cash flow. Many companies offer auction and liquidation services. Selection of the right auctioneer or liquidator…

    • Five Steps to Ensure Your Cell and Gene Therapy Product Is GMP Compliant

      Five Steps to Ensure Your Cell and Gene Therapy Product Is GMP Compliant

      When we think about CGTs what most often comes to mind is the early stage scientific innovation responsible for finding new ways to treat diseases.

    • APIs | Cytotoxics and High Potency Manufacturing | Facilities
      Flamma Arrives in the U.S.

      Flamma Arrives in the U.S.

      Italian CDMO sets down roots in the U.S. market with purchase of Teva facility.
      Tim Wright, Editor, Contract Pharma 10.15.19


    • Cytotoxics and High Potency Manufacturing
      Highly Potent Expansions

      Highly Potent Expansions

      CDMOs see HPAPI demand rising
      S. Harachand, Contributing Editor 09.16.19

    • Cytotoxics and High Potency Manufacturing
      High Containment & Cost Savings with Single Use Isolator Technology

      High Containment & Cost Savings with Single Use Isolator Technology

      The trend towards HPAPIs is driving the need for innovative containment systems.
      Scott Patterson, Vice President Commercial Sales, ILC Dover 09.16.19

    • Cytotoxics and High Potency Manufacturing
      Handling & Assessing HPAPIs

      Handling & Assessing HPAPIs

      As oncology pipelines grow, so too is the demand for highly potent materials, which require careful handling and containment.
      Jason Korbel, Technical Services Manager, Cambrex Charles City 09.16.19


    • Cytotoxics and High Potency Manufacturing
      API to ADC: A Journey Through High Potency

      API to ADC: A Journey Through High Potency

      This class of compounds represents a major advance in oncology research and treatment application.
      Maurits Janssen, Head Commercial Development API, Lonza Pharma & Biotech 09.16.19

    • Bio News | Breaking News | Industry News | Validation
      Viralgen Receives EMA cGMP Certification

      Viralgen Receives EMA cGMP Certification

      Confirms commitment to flexible and robust AAV manufacturing capability
      09.05.19

    • Breaking News | Collaborations & Alliances | Excipients | Industry News
      Sterling Starts Large-scale Production of Nanologica’s Silica Particles

      Sterling Starts Large-scale Production of Nanologica’s Silica Particles

      First commercial batch is expected to be delivered during 2021
      08.28.19


    • Bio News | Breaking News | Industry News | Promotions & Moves | QA/QC | Regulatory Affairs
      Goodwin Biotechnology Bolsters Quality & Regulatory Capabilities

      Goodwin Biotechnology Bolsters Quality & Regulatory Capabilities

      Names Gerald Orehostky as vice president of quality and regulatory operations
      08.07.19